Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.
Garioni M, Tschan VJ, Blukacz L, Nuciforo S, Parmentier R, Roma L, Coto-Llerena M, Pueschel H, Piscuoglio S, Vlajnic T, Stenner F, Seifert HH, Rentsch CA, Bubendorf L, Le Magnen C. Garioni M, et al. Among authors: stenner f. NPJ Precis Oncol. 2023 Nov 2;7(1):112. doi: 10.1038/s41698-023-00466-w. NPJ Precis Oncol. 2023. PMID: 37919480 Free PMC article.
Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer.
Bratic Hench I, Roma L, Conticelli F, Bubendorf L, Calgua B, Le Magnen C, Piscuoglio S, Rubin MA, Chirindel A, Nicolas GP, Vlajnic T, Zellweger T, Templeton AJ, Stenner F, Ruiz C, Rentsch C, Bubendorf L. Bratic Hench I, et al. Among authors: stenner f. Cancers (Basel). 2023 Dec 21;16(1):45. doi: 10.3390/cancers16010045. Cancers (Basel). 2023. PMID: 38201475 Free PMC article.
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner F, Templeton A, Schäfer N, Wild D, Chirindel A; all investigators on behalf of the SSNM Therapy Working Group. Neubauer MC, et al. Among authors: stenner f. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1185-1193. doi: 10.1007/s00259-023-06536-2. Epub 2023 Dec 1. Eur J Nucl Med Mol Imaging. 2024. PMID: 38038755 Free PMC article.
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Agerbaek M, Jha G, Stenner F, Ye D, Giudici F, Dutta S, Askelson M, Nasroulah F, Zhang J, Brophy L, Bajorin DF. Galsky MD, et al. Among authors: stenner f. J Clin Oncol. 2025 Jan;43(1):15-21. doi: 10.1200/JCO.24.00340. Epub 2024 Oct 11. J Clin Oncol. 2025. PMID: 39393026 Free PMC article. Clinical Trial.
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
Galsky MD, Bajorin DF, Witjes JA, Gschwend JE, Tomita Y, Nasroulah F, Li J, Collette S, Valderrama BP, Grimm MO, Appleman L, Gravis G, Necchi A, Ye D, Stenner F, Wind-Rotolo M, Zhang J, Ünsal-Kaçmaz K. Galsky MD, et al. Among authors: stenner f. Eur Urol. 2023 May;83(5):432-440. doi: 10.1016/j.eururo.2023.01.016. Epub 2023 Mar 2. Eur Urol. 2023. PMID: 36868932 Free PMC article.
Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas.
Ivanova VS, Menter T, Cui N, Leary P, Zinner C, Halter JP, Stenner F, Dirnhofer S, Müller A, Tzankov A. Ivanova VS, et al. Among authors: stenner f. Br J Haematol. 2025 Jan 7. doi: 10.1111/bjh.19952. Online ahead of print. Br J Haematol. 2025. PMID: 39777628
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.
König D, Sandholzer MT, Uzun S, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer DJ, Kettelhack C, Passweg JR, Holbro A, Baur K, Medinger M, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Kasenda B, Homicsko K, Matter M, Rodrigues Mantuano N, Zippelius A, Läubli H. König D, et al. Among authors: stenner f. Cancer Immunol Res. 2024 Jul 2;12(7):814-821. doi: 10.1158/2326-6066.CIR-23-0757. Cancer Immunol Res. 2024. PMID: 38631025
69 results